Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews.
about
Third-line systemic treatment for non-small cell lung cancerClinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic reviewQuality of Life in elderly patients with cancerIs the Evaluation of Quality of Life in NSCLC Trials Important? Are the Results to be Trusted?Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old ideaPatients' preferences: a discrete-choice experiment for treatment of non-small-cell lung cancerHow long and how well: oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments.Defining a standard set of patient-centred outcomes for lung cancer.Patient preference and contraindications in measuring quality of care: what do administrative data miss?Are the data on quality of life and patient reported outcomes from clinical trials of metastatic non-small-cell lung cancer important?First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view.Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up.Managing patients with lung cancer. Effective communication, palliative care, and guidelines are neededTraining recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferencesThe role of new agents in advanced non-small-cell lung carcinoma.Management of elderly patients with lung cancer.Epidemiology of lung cancer prognosis: quantity and quality of life.Trajectory of overall health from self-report and factors contributing to health declines among cancer survivors.Use of geriatric assessment for older adults in the oncology setting: a systematic review.Patients' perspectives on palliative chemotherapy of colorectal and non--colorectal cancer: a prospective study in a chemotherapy- experienced populationFunctional status declines among cancer survivors: trajectory and contributing factors.Development and validation of the Japanese version of the Decisional Conflict Scale to investigate the value of pharmacists' information: a before and after studyLung cancer--where are we today? Current advances in staging and nonsurgical treatment.The role of chemotherapy at the end of life: "when is enough, enough?".Lung cancer. 4: chemotherapy for non-small cell lung cancer: the end of the beginning.Lung cancer 7: management of lung cancer in elderly patients.Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?Lung cancer: district active treatment rates affect survival.Completion of the audit cycle: standardised nurse-led information for patients.Recruitment of patients with lung cancer into a randomised clinical trial: experience at two centres. On behalf of the Big Lung Trial Steering Committee.Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life.Chemotherapy in metastatic and locally advanced non-small cell lung cancer.Chemotherapy for cancer patients who present late.Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib.Prognostic understanding, quality of life and mood in patients undergoing hematopoietic stem cell transplantation.Patient comprehension and attitudes toward maintenance chemotherapy for lung cancerSafety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients.Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer.Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.
P2860
Q24194090-80CAEB9D-53DE-4842-93CE-ECDCE828CE1FQ24678961-8E74442A-77AE-4ADF-9053-87A1A8CB72B5Q24802727-45C394FF-CB9B-4BDF-A387-24DF9AAE9C88Q27006021-019152C4-115F-4857-9A01-338D9280EDBDQ27011282-B193BEA9-E33A-4030-8E5B-C01A0916B7DAQ28396145-9028DB71-DEF1-48C3-8634-70EDCC3F86D7Q30226892-322F7E87-F6A5-4AE2-873E-BEFB6FA27B78Q30276400-B7BF8C50-3217-4415-8831-B5AEC408EF60Q30644505-5B8F615B-BFB4-49B4-AB69-D24983F51AA9Q30830928-910F75D9-0CDC-4AA7-B66D-5EE57C6D5AA9Q33373493-4BFE03F6-8FF9-4240-BF47-E8CF783E4F15Q33627703-0DE6EC5C-7B98-43A8-B5AE-88EE546EBEFEQ33816683-3B665ACE-5FFF-4979-B31B-023AA7492DD9Q34067540-8C79931A-4780-4E73-9E98-526F6644A447Q34107800-24EC76A5-52F7-4E1D-816C-68C6D11ECF0AQ34107807-3CDDE762-D7C6-47FE-A043-C2848FADF813Q34135295-C275C7CF-9A38-45B8-B53A-497B90182200Q34145479-0017E00F-D0B4-4617-BBA6-4FB5CA31EDA6Q34360763-5D1AC659-D64D-4273-A341-6FBBD38C69DFQ34580422-82A6A43E-6832-4F3F-926D-4821FA1930E1Q34623432-9090D7A2-5803-4106-8096-04048AB2D245Q34675430-BAE9A79B-613D-4E51-89ED-8F981C9AA082Q34982142-B87815CF-6BAB-4BF5-9200-1AC17EE1DD68Q34997049-55A5A67D-5703-4191-BD55-58FD73640766Q35096015-D1AB6AB6-087F-4DFD-9961-18D765D52CBDQ35186819-137BF387-2E01-42E0-9FBD-968E6B9EF7B1Q35223735-A3476107-DEF1-467C-A971-A52A4050A73FQ35408328-082545B1-53C6-4BA3-AE30-72EE2CE0CFFDQ35518257-EE3A61D0-258C-4D9E-BA61-84831FA112FFQ35533824-940DC136-6A77-4A87-BDE5-5B355D2CBF46Q35536245-D0507161-87E8-4E9F-B15F-18D6C0D5F36EQ35543226-150236AF-ECF0-4C07-A4A9-D6EE2801CA24Q35802013-309F131B-8DF7-4186-A332-3FCF73530772Q35875986-B8BE49CA-47FA-4C3A-8309-4D1F4AACB289Q35920594-813316DD-E694-436E-87F1-F0F7DF0BDB76Q36236671-8C4786C2-EB0F-4529-8A23-C3D7E547585AQ36299985-5AB6E856-A9F4-4CBF-B6A1-1918E33FFE73Q36304283-16A1CA85-DF9A-409F-A054-093713431AA3Q36448679-D03896CC-D839-4B29-AD42-70B4CA6AB738Q36612331-95DF01EE-0028-419F-95F3-9C298453856A
P2860
Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews.
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Preferences for chemotherapy i ...... based on scripted interviews.
@ast
Preferences for chemotherapy i ...... based on scripted interviews.
@en
type
label
Preferences for chemotherapy i ...... based on scripted interviews.
@ast
Preferences for chemotherapy i ...... based on scripted interviews.
@en
prefLabel
Preferences for chemotherapy i ...... based on scripted interviews.
@ast
Preferences for chemotherapy i ...... based on scripted interviews.
@en
P2093
P2860
P356
P1433
P1476
Preferences for chemotherapy i ...... based on scripted interviews.
@en
P2093
G Silvestri
R Pritchard
P2860
P304
P356
10.1136/BMJ.317.7161.771
P407
P577
1998-09-01T00:00:00Z